Viscent

Viscent is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing first-in-class small molecule therapeutics for inflammatory and fibrotic diseases. The company's lead program, VT-001, is a potent and selective agonist of GPR120 (FFAR4), a nutrient-sensing receptor that plays a critical role in regulating metabolic and inflammatory pathways. Viscent is primarily targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other metabolic disorders. The company was founded by a team of experienced biotech executives with a track record in metabolic disease drug discovery. Viscent is backed by prominent life science investors including Samsara BioCapital and Marshall Wace.